Tracked deals
4
4 tracked deals across 2019-2026.
Private Equity Firm
Healthcare
Mérieux Equity Partners
Lyon, France
Mérieux Equity Partners is a multistage investment manager specialized in the healthcare & nutrition sectors via two dedicated platforms: Venture and Growth/Buyout. It is an independent general partner registered with the French financial markets authority (AMF) and manages funds supporting healthcare and nutrition companies.
- Focus Areas
- Healthcare, Life sciences, Healthcare & nutrition investing
- Website
- merieux-partners.com
Recent pace
1
1 tracked deal announced in the last 12 months.
Deal mix
Buyout
3 buyout · 1 growth capital
Mérieux Equity Partners Acquisition Volume by Year
Last 4 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
-
- Buyer
- Mérieux Equity Partners
- Target
- Health in Code (HiC)
- Industry
- Healthcare Services
- Location
- Spain
- Type
- Growth capital
Mérieux Equity Partners, via its buyout fund Mérieux Participations 4 (MP4), has made an investment in Health in Code (HiC) for a significant minority stake. The deal is intended to support and accelerate HiC’s next phase of growth and international expansion.
-
- Buyer
- Mérieux Equity Partners, Siparex, Normandie Participations
- Target
- Piercan
- Seller
- Lucas family (founding family), Other historical shareholders
- Industry
- Medical Devices
- Location
- Normandy, France
- Type
- Buyout
Mérieux Equity Partners' MP4 fund has signed a definitive agreement to acquire a controlling majority stake in Piercan, with Groupe Siparex and regional investor Normandie Participations investing alongside. The deal is a primary LBO that will support Piercan — a Normandy-based, global manufacturer of isolator and dry-box gloves for the pharmaceutical and nuclear industries — to improve industrial capabilities, pursue international expansion and diversify into new market segments; the founding Lucas family and other historical shareholders reinvest part of their proceeds.
-
December 16, 2021
- Buyer
- SK Capital Partners, Bpifrance, Nov Santé, Mérieux Equity Partners, Ardian, Eximium, SEQENS management team
- Target
- SEQENS
- Seller
- Eurazeo
- Industry
- Pharmaceuticals
- Location
- Auvergne-Rhône-Alpes, France
- Type
- Buyout
Funds advised by SK Capital Partners acquired a majority shareholding in SEQENS, investing alongside Bpifrance, Nov Santé, Mérieux Equity Partners, Ardian, Eximium and SEQENS' management. The deal includes the integration of Wavelength Pharmaceuticals into SEQENS and the prior divestiture of certain non-core mineral specialties assets; SEQENS emerges as a strengthened pharmaceutical CDMO with ~€1.1bn revenue and ~3,200 employees.
-
December 5, 2019
- Buyer
- IK Investment Partners (IK Small Cap II Fund), M9rieux Equity Partners
- Target
- Mabtech AB
- Industry
- Biotechnology
- Location
- Stockholm County, Sweden
- Type
- Buyout
IK Investment Partners’ IK Small Cap II Fund has agreed to acquire a majority stake in Mabtech AB, a Stockholm-based specialist in immune monitoring and developer of monoclonal antibodies, ELISpot/FluoroSpot kits and the IRIS reader. Mérieux Equity Partners takes a minority stake alongside IK, founders and management remain invested, and EQT Credit provided senior secured (unitranche) financing to support the transaction.
Related Acquisition Pages
Biotechnology Buyers & Acquisitions
1 tracked deal by Mérieux Equity Partners.
Healthcare Services Buyers & Acquisitions
1 tracked deal by Mérieux Equity Partners.
Medical Devices Buyers & Acquisitions
1 tracked deal by Mérieux Equity Partners.
Pharmaceuticals Buyers & Acquisitions
1 tracked deal by Mérieux Equity Partners.
Selling a company? Get in front of buyers like Mérieux Equity Partners
Turn tracked acquisition activity into an outreach-ready buyer list.